Literature DB >> 8950990

ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block.

K Nishii1, J H Kabarowski, D L Gibbons, S D Griffiths, I Titley, L M Wiedemann, M F Greaves.   

Abstract

Using a temperature-sensitive mutant of the p210 BCR-ABL gene, transfected into a growth factor-dependent cell line (BaF3), we show that transient BCR-ABL kinase expression increases single cell and clonogenic resistance to apoptosis arising from genotoxic damage induced by ionizing radiation and VP-16/etoposide. This effect is achieved in the absence of any detectable changes in the levels of BCL-2, BAX or BCL-x proteins and is independent of proliferative, MAP kinase-dependent effects of BCR-ABL kinase. In contrast to parental cells that transiently arrest in G2 and then apoptose, p210 BaF3 cells show a pronounced and sustained G2 arrest following radiation coupled with enhanced phosphorylation of cdc2. A cell cycle block in early M phase induced by the mitotic spindle poison, nocodazole, does not provide protection from apoptosis. Reversal of G2 arrest by caffeine abolishes the protective effect of BCR-ABL kinase. These data provide further insight into the transforming properties of BCR-ABL and are relevant to the clinical intransigence of Ph-positive leukaemias.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8950990

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  Molecular pathways to CML stem cells.

Authors:  Kristen N Rice; Catriona H M Jamieson
Journal:  Int J Hematol       Date:  2010-06-10       Impact factor: 2.490

2.  Wip1 contributes to cell homeostasis maintained by the steady-state level of Wtp53.

Authors:  Hwan Ki Park; Jayabal Panneerselvam; Fred Duafalia Dudimah; Guangzhi Dong; Sinto Sebastian; Jun Zhang; Peiwen Fei
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

3.  The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.

Authors:  M S Neshat; A B Raitano; H G Wang; J C Reed; C L Sawyers
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

Review 4.  Biological determinants of radioresistance and their remediation in pancreatic cancer.

Authors:  Parthasarathy Seshacharyulu; Michael J Baine; Joshua J Souchek; Melanie Menning; Sukhwinder Kaur; Ying Yan; Michel M Ouellette; Maneesh Jain; Chi Lin; Surinder K Batra
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-02-27       Impact factor: 10.680

5.  Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells.

Authors:  Lori Rink; Artur Slupianek; Tomasz Stoklosa; Margaret Nieborowska-Skorska; Katarzyna Urbanska; Ilona Seferynska; Krzysztof Reiss; Tomasz Skorski
Journal:  Blood       Date:  2007-04-12       Impact factor: 22.113

6.  Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.

Authors:  Artur Slupianek; Grazyna Hoser; Ireneusz Majsterek; Agnieszka Bronisz; Maciej Malecki; Janusz Blasiak; Richard Fishel; Tomasz Skorski
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

7.  p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl).

Authors:  A Di Cristofano; M Niki; M Zhao; F G Karnell; B Clarkson; W S Pear; L Van Aelst; P P Pandolfi
Journal:  J Exp Med       Date:  2001-08-06       Impact factor: 14.307

8.  Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status.

Authors:  Lisa Lange; Sarah Keppner-Witter; Juline Grigat; Birgit Spänkuch
Journal:  Oncotarget       Date:  2014-04-30

9.  Inflammatory interferon activates HIF-1α-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway.

Authors:  Yen-Hsiu Yeh; Ho-Fu Hsiao; Yen-Cheng Yeh; Tien-Wen Chen; Tsai-Kun Li
Journal:  J Exp Clin Cancer Res       Date:  2018-03-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.